• Crosstree Capital Partners sold its Strategic Advisory & Origination buy-side division to newly formed 7Sage Partners.
• 7Sage will be led by Gordon Ryerson and Michael Levin, both former Crosstree executives, retaining the existing buy-side team.
• Move tightens Crosstree’s focus on life-sciences sell-side advisory while allowing 7Sage to expand across broader healthcare.
• Existing client engagements will continue without interruption, with Crosstree and 7Sage planning to maintain a working partnership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crosstree Capital Partners, Inc published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.